Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России – ОСП «Российский геронтологический научно-клинический центр», Москва, Россия natalyavorobjeva@mail.ru
Список исп. литературыСкрыть список 1. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther. 2006; 24: 897–908. DOI: 10.1111/j.1365-2036.2006.03077.x 2. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955–62. DOI: 10.1016/S0140-6736(13)62343-0 3. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007; 177 (4): 347–51. DOI: 10.1503/cmaj.070186 4. Gao F, Chen X, Zhang J. Prevalence of gastric and small-intestinal mucosal injury in elderly patients taking enteric-coated aspirin by magnetically controlled capsule endoscopy. Gastroenterol Res Pract. 2019: 1582590. DOI: 10.1155/2019/1582590 5. Tziatzios G, Gkolfakis P, Papanikolaou IS, Triantafyllou K. Antithrombotic treatment is associated with small-bowel video capsule endoscopy positive findings in obscure gastrointestinal bleeding: A systematic review and meta-analysis. Dig Dis Sci. 2019; 64 (1): 15–24. DOI: 10.1007/s10620-018-5292-0 6. Watanabe T, Sugimori S, Kameda N et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008; 6 (11): 1279–82. DOI: 10.1016/j.cgh.2008.06.021 7. Iwamoto J, Mizokami Y, Saito Y et al. Small-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal bleeding. World J Gastroenterol. 2014; 20 (36): 13133–8. DOI: 10.3748/wjg.v20.i36.13133 8. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 Oganov RG, Simanenkov VI, Bakulin IG et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovasc Ther Prevention. 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 (in Russian). 9. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021; 20 (1): 2758. DOI: 10.15829/1728-8800-2021-2758 Simanenkov VI, Maev IV, Tkacheva ON et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovasc Ther Prevention. 2021; 20 (1): 2758. DOI: 10.15829/1728-8800-2021-2758 (in Russian). 10. Остроумова О.Д., Орлова И.Ю., Кочетков А.И. и др. Структура сопутствующих заболеваний органов пищеварения у пациентов, получающих прямые оральные антикоагулянты: результаты многоцентрового кросс-секционного фармакоэпидемиологического исследования. Терапия, 2022; 8 (10): 152–61. DOI: 10.18565/therapy.2022.10.152-161 Ostroumova OD, Orlova IY, Kochetkov AI et al. Structure of concomitant digestive diseases in patients receiving direct oral anticoagulants: results of a multicenter cross-sectional pharmacoepidemiological study. Therapy. 2022; 8 (10): 152–61. DOI: 10.18565/therapy.2022.10.152-161 (in Russian). 11. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017; 152 (4): 706–15. DOI: 10.1053/j.gastro.2017.01.031 12. Xie Y, Bowe B, Li T et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017; 7 (6): e015735. DOI: 10.1136/bmjopen-2016-015735 13. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018; 27 (4): 443–50. DOI: 10.1016/j.hlc.2017.10.020 14. Maggio M, Corsonello A, Ceda GP et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013; 173 (7): 518–23. DOI: 10.1001/jamainternmed.2013.2851 15. Tai FWD, McAlindon ME. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018; 34 (3): 175–82. DOI: 10.1097/MOG. 0000000000000427 16. Washio E, Esaki M, Maehata Y et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016; 14 (6): 809–15.e1. DOI: 10.1016/j. cgh.2015.10.022 17. Chen WC, Lin KH, Huang YT et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther. 2017; 45 (12): 1542–50. DOI: 10.1111/apt.14079 18. Chan EW, Lau WC, Leung WK et al. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology. 2015; 149 (3): 586–95.e3. DOI: 10.1053/j.gastro.2015.05.002 19. Maruyama K, Yamamoto T, Aoyagi H et al. Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants. Biomed Res Int. 2018; 2018: 7123607. DOI: 10.1155/2018/7123607 20. Youn SH, Lim H, Ju Y et al. Effect of gastroprotective agents on upper gastrointestinal bleeding in patients receiving direct oral anticoagulants. Scand J Gastroenterol. 2018; 53 (12): 1490–5. DOI: 10.1080/00365521.2018.1541478 21. Ткачева О.Н., Остроумова О.Д., Котовская Ю.В. и др. Депрескрайбинг ингибиторов протонной помпы у пациентов пожилого и старческого возраста. Клиническая фармакология и терапия. 2019; 28 (1): 70–4. DOI: 10.32756/0869- 5490-2019-1-70-74 Tkacheva ON, Ostroumova OD, Kotovskaya YuV et al. Deprescribing of proton pump inhibitors in elderly and senile patients. Clin Pharmacology Therapy. 2019; 28 (1): 70–4. DOI: 10.32756/0869- 5490-2019-1-70-74 (in Russian). 22. Tozawa K, Oshima T, Okugawa T et al. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig Dis Sci. 2014; 59 (8): 1885–90. DOI: 10.1007/s10620-014-3108-4 23. Pittayanon R, Piyachaturawat P, Rerknimitr R et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019; 34 (9): 1517–22. DOI: 10.1111/jgh.14671 24. Takeuchi K, Takayama S, Hashimoto E et al. Effect of rebamipide on gastric bleeding and ulcerogenic responses induced by aspirin plus clopidogrel under stimulation of acid secretion in rats. J Gastroenterol Hepatol. 2014; 29 (Suppl. 4): 37–46. DOI: 10.1111/jgh.12774 25. Zhang WT, Wang MR, Hua GD et al. Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis. Front Pharmacol. 2021; 12: 730681. DOI: 10.3389/fphar.2021.730681 26. Nishida U, Kato M, Nishida M et al. Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin. World J Gastroenterol. 2011; 17 (2): 226–30. DOI: 10.3748/wjg.v17.i2.226 27. Mizukami K, Murakami K, Abe T et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011; 17 (46): 5117–22. DOI: 10.3748/wjg.v17.i46.5117 28. Kurokawa S, Katsuki S, Fujita T et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014; 49 (2): 239–44. DOI: 10.1007/s00535-013-0805-2 29. Watanabe T, Takeuchi T, Handa O et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin Induced Moderate-to-Severe Small Intestinal Damage. PLoS One. 2015; 10 (4): e0122330. DOI: 10.1371/journal.pone.0122330 30. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013; 58 (7): 1991–2000. DOI: 10.1007/s10620-013-2606-0 31. Kovaleva A, Poluektova E, Maslennikov R et al. Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial. J Clin Med. 2023; 12 (18): 6064. DOI: 10.3390/jcm12186064 32. Остроумова О.Д., Орлова И.Ю., Кочетков А.И. и др. Структура назначения лекарственных препаратов гастропротективного действия у пациентов, получающих прямые оральные антикоагулянты: результаты многоцентрового кросс-секционного фармакоэпидемиологического исследования. Фарматека. 2022; 29 (13): 62–9. DOI: 10.18565/pharmateca.2022.13.62-69 Ostroumova OD, Orlova IY, Kochetkov AI et al. Structure of prescribing gastroprotective drugs in patients receiving direct oral anticoagulants: results of a multicenter cross-sectional pharmacoepidemiological study. Therapy. 2022; 8 (10): 152–61. DOI: 10.18565/pharmateca. 2022.13.62-69 (in Russian). 33. Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Терапия, 2021; 10: 23–41. DOI: 10.18565/therapy. 2021.10.23–41 Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy, 2021; 10: 23–41. DOI: 10.18565/therapy.2021.10.23–41 (in Russian). 34. Снижение риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Алгоритмы диагностики и лечения. Терапия, 2022; 5 (приложение): 150–163. Reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Algorithms of diagnostic and treatment. Therapy, 2022; 5 (supplement): 150–163. (In Russian).